Detalhe da pesquisa
1.
Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint era.
Cancer
; 125(4): 496-498, 2019 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30620399
2.
Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer.
Clin Cancer Res
; 29(16): 3237-3249, 2023 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37289191
3.
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis.
Eur J Cancer
; 177: 175-185, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36368251
4.
AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors.
Mol Cancer Res
; 19(3): 485-497, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33172976
5.
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.
Cancer Cell
; 39(3): 346-360.e7, 2021 03 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33482121
6.
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.
J Thorac Oncol
; 15(5): 777-791, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32068166
7.
Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC.
J Thorac Oncol
; 14(12): 2152-2163, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31470128